Low-dose ketamine is generally safe when administered in a supervised clinical setting with proper monitoring, but it carries real risks that increase significantly with unsupervised or at-home use. The standard therapeutic dose for depression is 0.5 mg/kg delivered intravenously over 40 minutes, which is far below the levels used for surgical anesthesia. At this dose, side effects are common but typically short-lived. The bigger safety questions revolve around how it’s given, how often it’s repeated, and whether anyone is watching while it happens.
What “Low Dose” Actually Means
In clinical research, low-dose ketamine most often refers to 0.5 mg/kg given as a slow intravenous infusion. For a 150-pound person, that works out to roughly 34 mg. Some studies have tested even lower amounts, ranging from 0.1 to 0.4 mg/kg intravenously, or around 50 mg delivered as a nasal spray. These are all considered “sub-anesthetic,” meaning they’re well below the threshold that would render someone unconscious.
The FDA-approved nasal spray product, esketamine (Spravato), uses a related but distinct form of the molecule and is only approved for treatment-resistant depression under strict in-office supervision. Compounded ketamine products, including oral tablets, lozenges, and nasal sprays prescribed by telehealth companies for at-home use, are not FDA-approved for any psychiatric condition. That distinction matters because compounded products haven’t been evaluated for safety, effectiveness, or quality before reaching patients.
Common Short-Term Side Effects
Most people who receive a single low-dose ketamine infusion will experience some side effects during or shortly after the session. The most frequently reported are dissociation (a feeling of detachment from your body or surroundings), dizziness, nausea, sedation, blurred vision, and headache. These effects typically begin within minutes of infusion and resolve within one to two hours.
A smaller number of people experience more unsettling reactions: vivid hallucinations, panic attacks, or agitation. These are sometimes called “emergence reactions” and are the main reason ketamine fell out of favor as a general anesthetic decades ago. At low doses these reactions are less intense, but they still occur, and they can be frightening for someone who isn’t expecting them. Blood pressure and heart rate also tend to rise temporarily during infusion, which is why cardiovascular monitoring is standard practice in clinical settings.
Who Should Avoid Ketamine
Ketamine stimulates the cardiovascular system, so people with uncontrolled high blood pressure, a history of stroke, or certain heart conditions face elevated risk. The FDA has also flagged concerns about respiratory depression, where breathing slows and becomes less effective. One adverse event report from 2023 involved a patient who experienced respiratory depression after taking compounded oral ketamine at home for PTSD.
People with a history of psychosis or active psychotic symptoms are generally considered poor candidates, since ketamine can induce or worsen hallucinations, delusions, and disordered thinking. The FDA has specifically warned that psychiatric events could be induced or worsened with compounded ketamine products, particularly when used at higher doses or more frequently than the approved esketamine protocol. A history of substance use disorder also raises the stakes, though the data on this is more nuanced than you might expect.
Addiction and Misuse Risk
Ketamine is a Schedule III controlled substance, and its potential for abuse is well established in recreational contexts. However, the clinical picture looks different at therapeutic doses. Available studies indicate that single or repeated ketamine administrations in professionally controlled settings have not resulted in misuse, dependence, or drug-seeking behavior in patients with treatment-resistant depression. The key phrase there is “professionally controlled settings.” When ketamine is dispensed for home use, particularly as lozenges or nasal sprays without close oversight, the guardrails that prevent misuse are largely removed. The FDA has raised specific concerns about the misuse and abuse potential of compounded at-home ketamine products.
Bladder and Liver Damage
Chronic ketamine use is linked to a painful and sometimes irreversible bladder condition called ulcerative cystitis. This involves inflammation and ulceration of the bladder lining, which can shrink bladder capacity and damage the ureters. The condition is most commonly seen in recreational users who take ketamine frequently and in large amounts, and some researchers believe adulterants mixed into street-grade ketamine contribute to the higher rates in that population. The urogenital and liver effects of ketamine appear to be dose-dependent, meaning the risk climbs with cumulative exposure.
For someone receiving a 0.5 mg/kg infusion once a week or every few weeks in a clinic, the risk of bladder damage is substantially lower than for a recreational user. But it isn’t zero, and it isn’t well-studied over long timeframes. Liver injury is another concern flagged in FDA-approved ketamine labeling, though again, reported cases tend to involve higher or more frequent dosing.
Effects on the Brain Over Time
Short-term cognitive effects like memory impairment and difficulty concentrating are well-documented during and shortly after ketamine sessions. The open question is whether these effects linger with repeated use. Small case series following patients who received various doses of ketamine for up to a year for depression or chronic pain suggest that some cognitive side effects may persist with prolonged use.
On the other hand, a study of patients receiving esketamine nasal spray two to three times per week found no worsening of cognitive performance after 44 weeks of maintenance treatment compared to baseline. Research on long-term recreational users paints a more concerning picture: chronic heavy use is associated with reduced gray matter volume, lower white matter integrity, and weaker connections between brain regions involved in thinking and perception. These structural changes may explain the memory and decision-making problems seen in habitual users. The gap between supervised low-dose treatment and heavy recreational use is enormous, but the long-term data on clinical patients remains thin.
Why Setting and Supervision Matter
The single biggest factor in ketamine safety isn’t the drug itself but the context in which it’s used. Clinical guidelines from major anesthesiology and pain medicine organizations recommend that patients receiving even sub-anesthetic ketamine infusions be monitored continuously by a trained healthcare provider. That provider should be able to manage airway complications and track vital signs throughout the session. Blood pressure, heart rate, oxygen levels, and level of consciousness are the core measurements.
At-home ketamine use strips away most of these protections. The FDA has issued multiple warnings about compounded ketamine products dispensed for home use, noting that without monitoring for sedation, dissociation, and changes in vital signs, patients face risk of serious adverse events. There is no FDA-approved dosing regimen for compounded ketamine nasal sprays or oral formulations, which means patients and prescribers are working without an established safety framework. Animal studies have also shown an association between racemic ketamine and brain lesions, though the implications of those findings for humans remain unclear.
Drug Interactions to Be Aware Of
Ketamine interacts with several commonly prescribed medications. Benzodiazepines, often used for anxiety, can increase the sedative effects and raise the risk of respiratory depression when combined with ketamine. Lamotrigine, a mood stabilizer frequently prescribed for bipolar disorder, has a complex interaction: research shows it can attenuate some of ketamine’s effects on the brain, and in one case report involving lamotrigine overdose, ketamine failed to produce its expected anesthetic effect entirely. Whether lamotrigine meaningfully blunts ketamine’s antidepressant benefit in typical clinical doses isn’t fully settled, but it’s worth discussing with your prescriber if you take it. Antipsychotic medications like risperidone have also been shown to dampen certain ketamine responses.
If you’re considering ketamine treatment, a complete medication review beforehand is essential. Some interactions affect safety, others affect whether the treatment will work at all.